Alzheimer's disease research, amyloid plaques, tau tangles, and cognitive decline
368 articles
A randomized study finds that disclosing financial compensation during recruitment calls lowered consent rates by up to 13 points in Alzheimer's research.
A Harvard-developed digital seed amplification assay can precisely quantify TDP-43 protein aggregates in CSF, offering a potential diagnostic breakthrough for frontotemporal dementia.
New research links excess astrocytic cholesterol to impaired brain clearance — a potential key mechanism driving Alzheimer's progression.
Arginine supplements reduced toxic amyloid buildup, brain inflammation, and behavioral decline in fly and mouse Alzheimer's models.
A roundup of recent FDA brain-health approvals including lecanemab's full Alzheimer's approval and a new glioma drug.
A memory clinic study finds 70% of patients tested positive for Alzheimer's pathology, with testing volumes exploding since new treatments arrived.
Combining polygenic and transcriptional risk scores from blood raises Alzheimer's detection accuracy, offering a less invasive screening path.
A new NEJM case report highlights cerebral amyloid angiopathy, a vascular brain condition closely tied to cognitive decline and stroke risk.
A Cochrane review of 20,000+ patients finds amyloid-clearing drugs offer no meaningful benefit and raise brain bleed and swelling risks.
Cognitive reserve helps language performance early in svPPA, but accelerates decline once brain volume drops significantly.
A 4-protein panel in neuronal extracellular vesicles outperforms standard plasma tests in flagging early Alzheimer's brain changes.
A comprehensive review examines how marine-derived bioactives like omega-3s, astaxanthin, and polysaccharides may combat chronic neuroinflammation underlying major neurodegenerative diseases.
